TRACEY L. MERSFELDER, PHARMD College of Pharmacy, Ferris State University, Grand Rapids, Michigan

Phenylpropanolamine and stroke: The study, the FDA ruling, the implications

ABSTRACT

Following a recent case-control study that linked the use of phenylpropanolamine (PPA) in diet aids to the risk of hemorrhagic stroke, the Food and Drug Administration requested that drug companies stop marketing products that contain PPA. Dozens of over-the-counter and prescription diet aids and cough and cold remedies will need to be reformulated or discontinued. This paper reviews the study and its implications for physicians.

KEY POINTS

Investigators in the Hemorrhagic Stroke Project interviewed patients who had recently suffered a hemorrhagic stroke and compared the prevalence of PPA use in this group with that in a group of control subjects matched for age and sex.

In women, the odds ratio for recent use of PPA in diet aids was 16.58 (95% CI 1.51–182.21, P = .02) for stroke patients compared with control subjects. No statistically significant relationship was found, however, between the use of PPA-containing cough and cold remedies and stroke in men or women, and no men in the study took PPA-containing diet aids.

Possible mechanisms of PPA-induced hemorrhagic stroke may be through hypertension, vasoconstriction, or both.

Physicians should counsel patients to avoid PPA-containing products and to look for alternatives.

PHENYLPROPANOLAMINE (PPA), a common ingredient in dozens of cough and cold remedies and diet aids, may cause hemorrhagic strokes in a small number of users, according to a recent study.^{1,2} The risk is small: the investigators estimated that one of every 107,000 to 3,268,000 women who take a PPA-containing diet pill may have a PPAinduced stroke within 3 days, and no statistically significant risk could be established with cough and cold remedies or in men. Nevertheless, with billions of doses of PPA products being sold in the United States,^{3,4} PPA might cause up to 500 cases of hemorrhagic stroke per year.

Acting on these data, the Food and Drug Administration (FDA) issued a warning to consumers to immediately stop taking PPAcontaining products and asked that manufacturers voluntarily withdraw these products immediately and replace PPA with a safer alternative.

This paper reviews the study on which the FDA actions were based and the implications for physicians and patients.

WHAT IS PPA?

PPA, a sympathomimetic amine, relieves nasal congestion via vasoconstriction, binding to alpha-adrenergic and beta-adrenergic receptors and stimulating release of norepinephrine. It also suppresses the appetite control center in the hypothalamus, aiding in weight loss.

In the United States, PPA was commercially available as a combination of two racemic structures (d- and l-norephedrine).



PPA was available a long time. First synthesized in 1910, it was initially introduced as a parenteral medication for maintenance of blood pressure.³ In the 1930s it began to be widely used in oral formulations as a cold remedy, and in the 1940s its popularity grew as a diet aid. Until the FDA ruling, PPA was available in dozens of over-the-counter diet aids (TABLE 1), cough, cold, and allergy products, (TABLE 2), and prescription medications (TABLE 3).

STROKE RISK SUSPECTED

Adverse effects reported with the use of PPA include hypertension, dizziness, headache, agitation, psychosis, insomnia, cardiac arrhythmias, seizures, and hemorrhagic stroke.

Over the years a number of cases were reported in which patients suffered hemorrhagic stroke after taking PPA. In a review of the literature, Lake et al⁵ listed 24 such cases reported up to 1990, and several more cases were reported since then.^{6–8} Other cases of hemorrhagic stroke in PPA users have been reported to the FDA, but this type of spontaneous reporting cannot determine an association or frequency of events.

The exact mechanism by which PPA might cause hemorrhagic stroke is unknown. It may be due to acute hypertension or arteritis-like vascular changes characterized by "beading" (multiple areas of focal arterial stenosis or constriction) or both.⁹

In the early 1970s, the FDA established the Nonprescription Drugs Advisory Committee to evaluate the safety and efficacy of all over-the-counter medications. The committee's recommendations are published regularly in the Federal Register. Products are classified as one of the following:

- Category I (safe and effective)
- Category II (ineffective or unsafe, and their use is prohibited)
- Category III (the data are insufficient or conflicting, but use is allowed until publication of the final monograph).

In the late 1970s, the review board recommended that PPA be listed as a category I drug for use in nasal decongestants, and in the

TABLE 1

Over-the-counter diet aids that contained phenylpropanolamine*

PRODUCT	STRENGTH OF PPA
Acutrim 16-hour Steady Control Timed-Release Tablets	75 mg
Acutrim Late Day	75 mg
Acutrim Maximum Strength Timed-Release Tablets	5 75 mg
AcuTrim Diet Gum	7.5 mg
Amfed T.D. Capsules	75 mg
Appedrine	25 mg
Control	75 mg
Dexatrim Caffeine Free Extended Duration Timed-Release Tablets	75 mg
Dexatrim Caffeine Free Maximum Strength Timed-Release Capsules	75 mg
Dexatrim Caffeine Free with Vitamin C Timed-Release Caplets	75 mg
Dieutrim T.D. Capsules	75 mg
Permathene-16 Maximum Strength	75 mg
Permathene-16 Plus Vitamin C	75 mg
Phenoxine	25 mg
Phenyldrine	75 mg
Protrim Caplets	37.5 mg
Protrim S.R. Caplets	75 mg
Spray-U-Thin	6.58 mg

PPA = phenylpropanolamine

*Many manufacturers are reformulating their products

ADAPTED FROM OLIN BR, EDITOR. NONPRESCRIPTION DIET AIDS. DRUG FACTS AND COMPARISONS. ST. LOUIS: FACTS & COMPARISONS, INC. 2000, AND DOERING PL. OVERWEIGHT AND OBESITY. IN: ALLEN LV, BERARDI RR, DESIMONE EM, EDS. HANDBOOK OF NONPRESCRIPTION DRUGS 12TH ED. 2000:476.

1980s it recommended category I listing for PPA use in appetite suppressants, with limits on the maximum daily dose. However, owing to concern about adverse effects and risk of hemorrhagic stroke, the FDA never finalized the category I status of PPA.^{10–12}

In an epidemiologic study of PPA and stroke published in 1984,¹³ Jick et al concluded that if there was any risk, it was small. These investigators looked at patients from a group health organization, all younger than 65 years, who were identified from prescriptions filled for PPA-containing products from 1977



to 1981. They calculated that the relative risk for having a hemorrhagic stroke when taking PPA was 0.58 (95% CI 0.03-2.9)— ie, there was a non-statistically significant trend toward *fewer* strokes in PPA users than in nonusers.

This study probably was not large enough to detect a difference in stroke incidence between users and nonusers of PPA in prescription products, and it did not alleviate concerns about PPA. Both the FDA and the manufacturers of PPA-containing products recommended another study be conducted to evaluate the risk of hemorrhagic stroke from taking PPA. As a result of this recommendation, the Hemorrhagic Stroke Project was formed.

THE HEMORRHAGIC STROKE PROJECT

The Hemorrhagic Stroke Project^{1,2} was a casecontrol study, which identified a group of stroke patients and compared them with a similar group of healthy people to see if there were statistically significant differences in the prevalence of PPA use between the two groups.

Inclusion criteria

Patients with symptomatic subarachnoid or intracerebral hemorrhage were recruited at 43 hospitals in the United States between December 1994 and July 1999. Subarachnoid hemorrhage was diagnosed on the basis of clinical symptoms and specific diagnostic information, and intracerebral hemorrhage was diagnosed by symptoms and a computed tomographic scan.

Female and male patients were eligible if they:

- Were between the ages of 18 and 49 years,
- Could undergo a complete interview,
- Did not have a history of a brain lesion, and
- Did not have a previous history of stroke.

Two control subjects, matched for age and sex, were identified for each patient within 30 days of the patient's stroke.

Why this particular mix? The main objective of the study was to evaluate the risk of hemorrhagic stroke in women 18 to 49 years of age. This age range was selected on the basis of demographic data from reported cases in the literature. In the review by Lake et al,⁵ all but three of the strokes were in people within this age range, and about 66% of cases were in women. Other cases reported after this review^{6,7} were in women ages 17 to 36. One reported case was in an infant.⁸ Although only a few reported cases were in men, the investigators wanted to evaluate potential risk in both sexes.

Methods

Stroke patients and control subjects were asked during a structured interview whether they had any cold symptoms during the 2 weeks before the stroke (or the same 2 weeks for the matched control subjects), whether they had taken any medications to treat the cold, and whether they had taken any other medications during this period. They were also specifically asked about the use of particular medications or classes of medications. To verify information about medications, they were asked to show the package, if available, and to pick out the medications they took from a book containing photographs of packages.

Similarities and differences between the groups

The stroke patients (N = 702) and the matched control subjects (N = 1,376) did not differ significantly in age, sex, history of diabetes, use of oral contraceptives, or cold or influenza-like symptoms.

The stroke patients, however, had higher rates of risk factors for stroke such as hypertension, smoking, and family history of hemorrhagic stroke. Compared with the matched controls, more of the stroke patients were black, more had used cocaine on the day of the stroke or the preceding day, more used alcohol regularly, and more had used a product that contained nicotine or caffeine in the 3 days preceding the stroke. The stroke patients also had a lower average level of education, and fewer of them had used non-steroidal antiinflammatory drugs in the 3-day window.

More women stroke patients took PPA diet aids

Of the 383 stroke patients who were women, 6 (1.8%) had taken a diet pill that contained PPA within the 3 days preceding their stroke, com-

Only 6 women in the stroke group had taken a PPA diet aid

TABLE 2

Over-the-counter cough and cold products that contained phenylpropanolamine*

PRODUCT STRENGTH OF PPA		PRODUCT STRENGTH OF PPA		
Allerest Maximum Strength 12 Hour Caplets	75 mg	Coricidin Maximum Strength Sinus Headache	12.5 mg	
Alka-Seltzer Cold Medicine	20 mg	Covangesic	12.5 mg	
Alka-Seltzer Plus Cold Tablets	24.08 mg	Dapacin Cold	12.5 mg	
Alka-Seltzer Plus Cold & Cough	20 mg	Demazin Syrup	12.5 mg/5 mL	
Alka-Seltzer Plus Cold & Cough Medicine	20 mg	Demazin Tablets	25 mg	
Effervescent Tablets		Diamaphen Elixir	12.5 mg/5 mL	
Alka-Seltzer Plus Night-Time Cold	20 mg	Diamaphen Release	75 mg	
Anatuss Syrup	25 mg/5 mL	Diamaphen Tablets	25 mg	
Antihist-D tablets, extended release	75 mg	Dimetapp 4-Hour Liqui-Gels	25 mg	
A.R.M.	25 mg	Dimetapp Cold & Allergy Chewable Tablets	6.25 mg	
BC Cold-Sinus Powder	25 mg	Dimetapp Cold & Flu	12.5 mg	
BC Cold-Sinus-Allergy Powder	25 mg	Dimetapp Cold & Cough Maximum	25 mg	
Bromaline Elixir	12.5 mg/5 mL	Strength Liqui-Gels		
Bromanate Elixir	12.5 mg/5 mL	Dimetapp DM Elixir	12.5 mg/5 mL	
Bromatapp	75 mg	Dimetapp Elixir	12.5 mg/5 mL	
Children's Allerest	9.4 mg	Dimetapp Extentabs	75 mg	
Cheracol Plus Liquid	8.3 mg/5 mL	Dimetapp Tablets	25 mg	
Chlor-Rest	18.7 mg	Duadacin	12.5 mg	
Chlor-Trimeton Allergy-Sinus	12.5 mg	Entac	20 mg/5 mL	
Cold & Allergy Elixir	12.5 mg/5 mL	Entex Liquid	20 mg/5 mL	
Cold & Allergy DM	12.5 mg/5 mL	Gelpirin-CCF	12.5 mg	
Cold-Gest Cold Capsules	75 mg	Genamin Cold Syrup	6.25 mg/5 mL	
Cold Relief	12.5 mg	Genamin Expectorant Liquid	12.5 mg/5 mL	
Coldloc Elixir	20 mg/5 mL	Genatap Elixir	12.5 mg/5 mL	
Comtrex Liqui-Gels	12.5 mg	Gencold	75 mg	
Comtrex Maximum Strength Cold & Flu	12.5 mg	GuiaCough CF Liquid	12.5 mg/5 mL	
Comtroy Maximum Strongth Cold/Elu	12.5 mg	Guaifenex Liquid	20 mg/5 mL	
Relief Liqui-Gels	12.5 mg	Guiatuss CF Liquid	12.5 mg/5 mL	
Comtrex Max Strength Multi-Symptom	12.5 mg	Histosal	20 mg	
Cold & Flu Relief Liqui-Gels	5	Ipsatol Cough Formula Liquid for Children	9 mg/5 mL	
Conex Syrup	12.5 mg/5 mL	Konhane Cough & Cold Formula Liquid	12.5 mg/5 ml	
Congestant D	12.5 mg	Maximum Strength Cold & Allergy	25 mg	
Contac Maximum Strength 12 Hour Caplet	75 mg	4-Hour Liquid Gelcaps	25 mg	
Contac Severe Cold & Flu Maximum	12.5 mg	Maximum Strength Comtrex Liqui-Gels	12.5 mg	
Conture Liquid	20 mg/5 ml	Myminic Expectorant Liquid	12.5 mg/5 mL	
Contrass Liquia	20 mg/5 mg	Myminicol Liquid	12.5 mg/5 mL	
	12.5 mg	Naldecon DX Adult Liquid	12.5 mg/5 mL	

214 CLEVELAND CLINIC JOURNAL OF MEDICINE VOLUME 68 • NUMBER 3 MARCH 2001 Downloaded from www.ccjm.org on July 22, 2025. For personal use only. All other uses require permission.



PRODUCT	STRENGTH OF PPA	PRODUCT	STRENGTH OF PPA
Naldecon DX Children's Syrup	6.25 mg/5 mL	Tavist D	75 mg
Naldecon DX Pediatric Drops	6.25 mg/1 mL	Teldrin 12-Hour Allergy Relief Capsules	75 mg
Naldecon EX Children's Syrup	6.25 mg/5 mL	Temazin Cold Syrup	12.5 mg/5 mL
Naldecon EX Pediatric Drops	6.25 mg/1 mL	Threamine DM Syrup	12.5 mg/5 mL
Nadelate DX Adult Liquid	12.5 mg/5 mL	Thera-Hist Syrup	12.5 mg/5 mL
Night-Time Effervescent Cold Tablets	15 mg	Triactin	6.25 mg/5 mL
Orthoxicol Cough Syrup	8.3 mg/5 mL	Triactin Syrup	6.25 mg/5 mL
Pedicon DX Pediatric Drops	6.25 mg/1 mL	Triaminic-12	75 mg
Pediacon DX Children's Syrup	6.25mg/5 mL	Triaminic Allergy	25 mg
Pediacon EX Pediatric Drops	6.25 mg/1 mL	Triaminic Chewable Tablets	6.25 mg
Pediatuss D.E. Drops	6.25 mg/1 mL	Triaminic Cold	12.5 mg
Pediatuss Liquid	12.5 mg/5 mL	Triaminic DM Cough Relief Syrup	6.25 mg/5 mL
Phenadex Children's Cough/Cold Drops	6.25 mg/1 mL	Triaminic Expectorant, Chest & Head	6.25mg/5 mL
Phenadex Pediatric Cough and Cold Drops	6.25 mg/1 mL	Congestion Liquid	
Pyrroxate Caplet	25 mg	Triaminic Expectorant Liquid	6.25 mg/5 mL
Rescon Liquid	12.5 mg/5 mL	Triaminic Syrup	6.25 mg/5 mL
Rhinocaps	20 mg	Triaminic Syrup Cold & Allergy	6.25 mg/5 mL
Robafen CF Liquid	12.5 mg/5 mL	Triaminicin Cold, Allergy, Sinus Tablets	25 mg
Robatussin-CF Liquid	12.5 mg/5 mL	Triaminicol Multi-Symptom Cough and Cold	12.5 mg
Saleto-CF	12.5 mg	Triaminicol Multi-Symptom Cough	12.5 mg/5 mL
Saleto-D	18 mg	Triaminical Multi Symptom Poliof Colds	6.25 mg/5 ml
Silactin Expectorant	6.25 mg/5 mL	with Coughs Liquid	0.25 mg/5 mL
Silactin Syrup	12.5 mg/5 mL	Tricodene Forte Liquid	12.5 mg/5 mL
Silaminic Expectorant Liquid	12.5 mg/5 mL	Tricodene NN Liquid	12.5 mg/5 mL
Sildicon-E Pediatric Drops	6.25 mg/1 mL	Tricodene Pediatric Cough & Cold Liquid	12.5 mg/5 mL
Siltapp with Dextromethorphan HBr Cold	12.5 mg/5 mL	Triminol Cough Syrup	12.5 mg/5 mL
& Cough Elixir		Tri-Nefrin Extra Strength	25 mg
Siltussin-CF Liquid	12.5 mg/5 mL	Triphenyl Expectorant Liquid	12.5 mg/5 mL
Sil-Tex Liquid	20 mg/5 mL	Triphenyl Syrup	6.25 mg/5 mL
Sinapils	12.5 mg	Tussin CF Liquid	12.5 mg/5 mL
Sinulin	25 mg	Vicks DayQuil Allergy Relief 4-Hour Tablets	25 mg
Snaplets-DM Granules	6.25 mg	Vicks DayQuil Allergy Relief 12 Hour Tablets	5 75 mg
Snalplets-EX Granules	6.25 mg	Vicks DayQuil Sinus Pressure & Congestion	25 mg
Snaplets-Multi Granules	6.25 mg	Relief Caplets	
Spec-T Sore Throat/Decongestant Lozenges	10.5 mg	PPA = phenylpropanolamine	oducto
Statuss Expectorant Liquid St. Joseph Cold Tablets for Children	12.5 mg/5 mL 3.125 mg	ADAPTED FROM OLIN BR, EDITOR. RESPIRATORY COMBINATION AND COMPARISONS. ST. LOUIS: FACTS & COMPARISONS, IN ORDERS RELATED TO COLD AND ALLERGY. IN: ALLEN IV, BERA	DOUCTS ON PRODUCTS. DRUG FACTS C. 2000, AND TIETZE KJ. DIS ARDI RR, DESIMONE EM, EDS ISS 13TH ED. 2000;182–184

CLEVELAND CLINIC JOURNAL OF MEDICINE VOLUME 68 • NUMBER 3

TABLE 3

Prescription products that contained phenylpropanolamine*

PRODUCT	STRENGTH OF PPA	PRODUCT	STRENGTH OF PPA
Alumadrine	25 mg	Guiatex	45 mg
Ami-Tex LA	75 mg	Guiatex LA	75 mg
Anatuss	25 mg	Guiatex Liquid	20 mg/5 mL
Aquatab C	75 mg	Histade	75 mg
Aquatab D	75 mg	Histalet Forte	50 mg
Atrohist Plus	50 mg	Hista-Vadrin	40 mg
Bromanate DC Cough Syrup	12.5 mg/5 mL	Histex HC Syrup	6 mg/5 mL
Bromphen DC w/ Codeine Cough Syrup	12.5 mg/5 mL	Histine DM Syrup	12.5 mg/5 mL
Bromphen/DM/PPA Syrup	12.5 mg/5 mL	Hycomine Pediatric Syrup	12.5 mg/5 mL
Bromphen T.D.	15 mg	Hycomine Syrup	25 mg/5 mL
Brompheniramine DC	12.5 mg/5 mL	Hydrocodone PA Pediatric Syrup	12.5 mg/5 mL
Codamine Pediatric Syrup	12.5 mg/5 mL	Hydrocodone PA Syrup	25 mg/5 mL
Codamine Syrup	25 mg/5 mL	lohist Elixir	12.5 mg/5 mL
Codegest Expectorant Liquid	12.5 mg/5 mL	Iohist DM Syrup	12.5 mg/5 mL
Coldloc-LA	75 mg	Liqui-Histine-D Elixir	12.5 mg/5 mL
Conex with Codeine Syrup	12.5 mg/5 mL	Liqui-Histine DM Syrup	12.5 mg/5 mL
Cophene-X	10 mg	Myphetane DC Cough Syrup	12.5 mg/5 mL
Deconhist L.A.	50 mg	Naldecon	40 mg
Dimetane-DC Cough Syrup	12.5 mg/5 mL	Naldecon CX Adult Liquid	12.5 mg/5 mL
Drize	75 mg	Naldelate Pediatric Syrup	5 mg/5 mL
Dura-Gest	45 mg	Naldelate Syrup	20 mg/5 mL
Dura-Vent	75 mg	Nalgest	40 mg
Dura-Vent/A	75 mg	Nalgest Pediatric Drops	5 mg/1 mL
Enomine	45 mg	Nalgest Pediatric Syrup	5 mg/5 mL
Endal Expectorant Syrup	12.5 mg/5 mL	Nalgest Syrup	20 mg/5 mL
Entex	45 mg	Naldecon Pediatric Drops	5 mg/1 mL
Entex LA	75 mg	Naldecon Pediatric Syrup	5 mg/5 mL
Exgest LA	75 mg	Naldecon Syrup	20 mg/5 mL
Guaifenex PPA 75	75 mg	Nolamine	50 mg
Guaipax	75 mg	Norel Plus	25 mg

pared with 1 (0.1%) of the 750 control subjects who were women. After adjusting for the higher prevalence of risk factors for stroke (smoking, hypertension, black race, and lower education) among the stroke patients, the investigators calculated the odds ratio for having taken a PPA diet pill among women stroke patients at 16.58 (95% CI 1.51–182.21; P = .02).

What is an odds ratio? An odds ratio is the ratio of the odds of an event occurring in one group to the odds of the event in another group. This differs somewhat from the more commonly used relative risk, which is the ratio of the percentages of people in each group who had the event. Without adjustment, the odds ratio in this study would be: (6 women stroke patients taking PPA / 377 women stroke patients not taking PPA) / (91 women control subjects taking PPA / 749 women control subjects not taking PPA) = approximately 12. An odds ratio of 1, like a relative risk of 1, would indicate no difference between the groups.

The association was only in women, and only with diet aids. None of the men in the study had taken a PPA-containing diet pill not one. For women who used PPA-containing cough or cold remedies, the odds ratio was only 1.54, which was not statistically significant. For men who had taken a PPA-containing cough or cold remedy the odds ratio was



PRODUCT	STRENGTH OF PPA	PRODUCT	STRENGTH OF PPA
Ordrine AT Extended-Release	75 mg	Tamine S.R.	15 mg
Ornade Spansules	75 mg	T-Koff Liquid	20 mg/5 mL
Pannaz	75 mg	Triaminic Expectorant with Codeine Liquid	12.5 mg/5 mL
Partuss LA	75 mg	Triaminic Expectorant DH Liquid	12.5 mg/5 mL
Phanadex Cough Syrup	25 mg/5 mL	Trihist-CS Syrup	12.5 mg/5 mL
Phenahist-TRTablets	50 mg	Trihist-DM	12.5 mg/5 mL
Phenate	40 mg	TRINKOF-D	37.5 mg
Phenchlor S.H.A.	50 mg	Tri-Phen-Chlor	40 mg
Phenylfenesin LA	75 mg	Tri-Phen-Chlor Pediatric Drops	5 mg/1 mL
Poly-Histine CS Syrup	12.5 mg/5 mL	Tri-Phen-Chlor Pediatric Syrup	5 mg/5 mL
Poly-Histine-D Capsules	50 mg	Tri-Phen-Chlor Syrup	20 mg/5 mL
Poly-Histine-D Eixir	12.5 mg/5 mL	Tri-Phen-Mine Pediatric Drops	5 mg/1 mL
Poly-Histine-D Ped Caps	25 mg	Tri-Phen-Mine Pediatric Syrup	5 mg/5 mL
Poly-Histine DM Syrup	12.5 mg/5 mL	Tri-Phen-Mine S.R.	40 mg
Profen II	37.5 mg	Tusquelin Syrup	5 mg/5 mL
Profen II DM	37.5 mg	Tussanil DH	25 mg
Profen LA	75 mg	Tuss-Allergine Modified T.D.	75 mg
Resaid	75 mg	Tussogest Extended Release	75 mg
Rescap-D S.R.	75 mg	Tuss-Ornade Liquid	12.5 mg/5 mL
Rhinolar-EX	75 mg	Tuss-Ornade Spansules	75 mg
Rolatuss with Hydrocodone Liquid	3.3 mg/5 mL	ULR-LA	75 mg
Ru-Tuss with Hydrocodone Liquid	3.3 mg/5 mL	Uni-Decon	40 mg
Rymed-TR	75 mg	Vanex Forte	50 mg
SINUvent	75 mg	Vanex Forte-R	75 mg
S-T Forte Syrup	5 mg	Vetuss HC Syrup	3.3 mg/5 mL
Stahist	50 mg		
Stamoist LA	75 mg	PPA = phenylpropanolamine	duata
Statuss Espectorant Liquid	12.5 mg/5 mL	ADAPTED FROM OLINIBRIED TO RESPIRATORY COMPLIANTIC	
Statuss Green Liquid	3.3 mg/5 mL	AND COMPARISONS. ST. LOUIS: FACTS & COMPARISONS, INC	2000, AND TIETZE KJ. DIS

ORDERS RELATED TO COLD AND TALEBRGY, IN: ALLEN IV, BERARDI RR, DESIMONE EM, EDS. HANDBOOK OF NONPRESCRIPTION DRUGS 12TH ED. 2000:183–184.

0.62, which was not statistically significant. **TABLE 4** shows other analyses for PPA use in the two groups.

Extrapolating from these data, the investigators estimated that PPA might cause one hemorrhagic stroke in every 107,000 to 3,268,000 women within 3 days of taking a PPA-containing diet pill, which translates to about 200 to 500 hemorrhagic strokes each year in the United States.

Limitations of the study

Case-control studies in general cannot establish causation, they can only suggest an association. In particular, the Hemorrhagic Stroke Project had several limitations.

Potential bias. One limitation of the Hemorrhagic Stroke Project is the possible introduction of biases such as temporal-precedence bias, recall bias, and selection bias. The investigators attempted to minimize these biases in their study design, for example, by carefully structuring the interviews and by asking about all medication use within the preceding 2 weeks, not just 3 days.

Types of stroke included. The study included patients with stroke due to either intracerebral hemorrhage or subarachnoid hemorrhage. In a recent review, Leppälä et al¹⁴ evaluated risk factors for different stroke

TABLE 4

The Hemorrhagic Stroke Study: Association between phenylpropanolamine use and hemorrhagic stroke

VARIABLE	STROKE PATIENTS	CONTROL SUBJECTS	ADJUSTED MATCHED ODDS RATIO* AND 95% CI	<i>P</i> VALUE
Women Number in analysis	383	750		
Used a PPA diet pill [†]	6 (1.6%)	1 (0.1%)	16.58 (1.51–182.21)	.01
Used a PPA cough or cold remedy	16 (4.2%)	19 (2.5%)	1.54 (0.76–3.14)	.23
Used any PPA product	21 (5.5%)	20 (2.7%)	1.98 (1.00–3.90)	.05
Used a PPA product for the first time [‡]	7 (1.8%)	4 (0.4%)	3.13 (0.86–11.46)	.08
Men Number in analysis	319	626		
Used a PPA-containing diet pill	0	0		
Used a PPA cough or cold remedy	6 (1.9%)	13 (2.1%)	0.62 (0.20–1.92)	.41
Used any PPA product	6 (1.9%)	13 (2.1%)	0.62 (0.20-1.92)	.41
Used a PPA product for the first time	1 (0.3%)	1 0.2%)	2.95 (0.15–59.59)	.48

*Adjusted for smoking, hypertension, race, and level of education

[†]Within 3 days preceding the onset of symptoms

+Within 24 hours before the onset of symptoms, and had not used any other such products the preceding 2 weeks

ADAPTED FROM KERNAN WN. VISCOLI CM, BRASS LM, ET AL. PHENYLPROPANOLAMINE AND THE RISK OF HEMORRHAGIC STROKE. N ENGL J MED 2000; 343:1826–1832.

Many manufacturers are reformulating PPA-containing products

subtypes and demonstrated that the risk factor profiles for subarachnoid hemorrhage and intracerebral hemorrhage had little in common. These investigators suggest that studies not ignore stroke subtyping, in view of the risk of forming misleading associations. However, they did not specifically look at medication use as a risk factor in their evaluation, which was the focus of the Hemorrhagic Stroke Project.

Combination effect with caffeine. Combining medications can sometimes lead to an increase in adverse effects. A diet aid that contained the combination of PPA and caffeine was removed from the market in the 1980s because of unacceptable adverse drug reactions and abuse potential.^{2,5}

In the Hemorrhagic Stroke Project, 7% of stroke patients reported ingesting caffeine,

compared with 2.9% of the matched control subjects (P < .01). However, the amount or type of caffeine consumed was not reported. Although the odds ratio did not change after the investigators performed a basic conditional logistic model to account for reported caffeine use by study patients,² given the high coffee consumption in the United States, the combination effect of these two medications should not be ignored.

Combination effect with herbal products. Another potentially harmful combination not addressed in the study was herbal or natural products taken with PPA. Some of these products contain ephedrine-like substances that could possibly enhance the adverse effects of PPA when ingested concurrently. Examples of these include Ma huang, Ephedra herba, and Ephedra sinensis.

Does the PPA dose matter?

The Hemorrhagic Stroke Project showed a trend toward a dose-effect relationship: ie, there was a higher odds ratio in the people taking more than 75 mg per day than in those who took less than 75 mg per day. In contrast, Lake et al⁵ reported that of the 24 reported cases of intracranial hemorrhage, 9 were in patients who took the recommended amount of PPA. The other 15 cases were in people who either overused or overdosed on PPA. The authors concluded from the case reports that a dose-response pattern was not evident from the data available.

Notably, most of the cases reported were not associated with use of cough and cold remedies in recommended doses. Cough and cold remedies generally contain less PPA than the diet aids; also unlike the diet aids, they are not typically formulated as sustained-release products. It is difficult, however, to make a strong conclusion from a series of case reports. A larger study powered to detect a difference in dosages of PPA and the risk of hemorrhagic stroke would be required.

IMPLICATIONS

Although the overall risk of PPA-induced hemorrhagic stroke is low (and not statistically significant for cough and cold products), the inability to predict who is at risk, along with the debilitating effects of stroke, produces serious concerns.

The FDA does not consider PPA to be safe for use in over-the-counter or prescription medications. The results of the Hemorrhagic Stroke Project prompted the FDA to:

• Recommend that manufacturers voluntarily discontinue marketing all over-thecounter and prescription medications containing PPA.

• Issue a public health advisory about the safety of PPA on October 6, 2000, indicating that over-the-counter medications containing PPA should not be recommended to patients for weight control or for symptomatic cold relief, and that prescription medications containing PPA should also be avoided.

TABLE 5

Cough and cold products with pseudoephedrine

Alka-Seltzer Plus Cold & Cough Medicine Liqui-Gels Alka-Seltzer Plus Flu & Body Aches Liqui-Gels Comtrex Day and Night Maximum Strength Cold and Flu Relief Contac Non-Drowsy Novahistine DH Liquid PediaCare Cough-Cold Liquid Pediacare Infants' Decongestant Plus Cough Drops Robitussin Night-Time Cold Softgels **Robitussin PE Syrup** Robitussin Pediatric Night Relief Liquid **Robitussin Severe Congestion Liqui-Gels** Sudafed Severe Cold TheraFlu Cold & Cough Medicine NightTime TheraFlu Maximum Strenght Non-Drowsy Caplets Triaminic AM Non-Drowsy Cough & Decongestant Triaminic Sore Throat, Throat Pain & cough Liquid Tylenol Cold Multi-Symptom Tylenol Cold No Drowsiness Tylenol Children's Cold Plus Cough Chewable Vicks 44M Soothing Cough, Cold & Flu Relief Vicks DayQuil Multi-Symptom Cold & Flu Relief LiquiCaps Vicks DayQuil Multi-Symptom Cold & Flu Relief Vicks NyQuil Children's Cold & Cough Relief Vicks NyQuil Multi-Symptom Cold & Flu Relief Liquid

ADAPTED FROM OLIN BR, EDITOR. RESPIRATORY COMBINATION PRODUCTS. DRUG FACTS AND COMPARISONS. ST. LOUIS: FACTS & COMPARISONS, INC. 2000, AND TIETZE KJ. DISORDERS RELATED TO COLD AND ALLERGY. IN: ALLEN LV, BERARDI RR, DESIMONE EM, EDS. HANDBOOK OF NONPRESCRIPTION DRUGS 12TH ED. 2000:183–184.

Alternatives to PPA

Oral cough, cold, and allergy products containing pseudoephedrine (TABLE 5) or nasal decongestants such as oxymetazoline or phenylephrine are alternatives for patients seeking relief from symptoms. Caution still should be taken when recommending pseudoephedrine to patients with hypertension, hyperthyroidism, diabetes mellitus, coronary heart disease, ischemic heart disease, elevated intraocular pressure, or prostatic hypertrophy, because decongestants may exacerbate these diseases.¹⁵ Although no studies have evaluated the occurrence of hemorrhagic stroke with the use of pseudoephedrine, some suggest that PPA may not be the only alpha-adrenergic agonist that can cause serious adverse effects.¹⁶ Sodium chloride nasal spray may benefit some patients without carrying the risk of serious side effects.

In view of the overwhelming number of over-the-counter products available, patients should ask their pharmacist for assistance in selecting a medication best suited for their

REFERENCES

- Kernan WN, Viscoli CM, Brass LM, et al. Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med 2000; 343:1826–1832.
- Horwitz RI, Brass LM, Kernan WN, Viscoli CM. Phenylpropanolamine and risk of hemorrhagic stroke: final report of the Hemorrhagic Stroke Project. http://www.fda.gov/ohrms/dockets/ac/00/backgrd/3647bl_t ab19.doc. Accessed 1/23/01.
- Silverman HI. A history of therapeutic uses of phenylpropanolamine in North America. In Morgan JP, Kagan DV, Brody JS, editors. Phenylpropanolamine: risks, benefits, and controversies. New York: Praeger Publishers, 1985:11–24.
- Morgan JP. Over-the-counter medication: availability and issues. In Morgan JP, Kagan DV, Brody JS, editors. Phenylpropanolamine: risks, benefits, and controversies. New York: Praeger Publishers, 1985:3–10.
- Lake CR, Gallant S, Masson E, Miller P. Adverse drug effects attributed to phenylpropanolamine: a review of 142 case reports. Am J Med 1990; 89:195–208.
- Forman HP, Levin S, Stewart B, Patel M, Feinstein S. Cerebral vasculitis and hemorrhage in an adolescent taking diet pills containing phenylpropanolamine: case report and review of literature. Pediatrics 1989; 83:737–741.
- Sloan MA, Kittner SJ, Rigamonti D, Price TR. Occurrence of stroke associated with use/abuse of drugs. Neurology 1991; 41:1358–1364.
- Hamilton RS, Sharieff G. Phenylpropanolamine-associated intracranial hemorrhage in an infant. Am J Emerg Med 2000; 18:343–345.
- 9. Kase CS, Mohr JP, Caplan LR. Intracerebral hemorrhage. In

CI'I

CRED

symptoms. If your patients have questions about over-the-counter medications they have at home, suggest they bring them in the original packaging to one of their health care providers or pharmacist, since many manufacturers have or are in the process of reformulating PPA-containing products.

Acknowledgments. I wish to thank Dr. Teresa Seo and Dr. Steven Durst for their helpful comments on this manuscript.

Barnett HJM, Mohr JP, Stein BM, Yatsu FM, editors. Stroke pathophysiology, diagnosis, and management. New York: Churchill Livingstone, 1998:659–660.

- Wertheimer AI. Phenylpropanolamine preparations, marketing, and economics: U.S. and abroad. In Morgan JP, Kagan DV, Brody JS, editors. Phenylpropanolamine: risks, benefits, and controversies. New York: Praeger Publishers, 1985:37–52.
- Food and Drug Administration Center for Drug Evaluation and Research. Public health advisory. Subject: safety of phenylpropanolamine. http://www.fda.gov/cder/drug/infopage/ppa/advisory.htm. Accessed 1/23/01.
- Food and Drug Administration Nonprescription Drugs Advisory Committee. The safety of phenylpropanolamine hydrochloride (PPA) used in OTC weight control and nasal decongestant drug products. http://www.fda.gov/ohrms/dockets/ac/00/backgrd/3647b1. htm. Accessed 1/23/01.
- Jick H, Aselton P, Hunter JR. Phenylpropanolamine and cerebral haemorrhage [letter]. Lancet 1984; 1:1017.
- Leppälä JM, Virtamo J, Fogelholm R, Albanes D, Heinonen OP. Different risk factors for different stroke subtypes association of blood pressure, cholesterol, and antioxidants. Stroke 1999; 30:2535–2540.
- Tietze KJ. Disorders related to cold and allergy. In: Allen LV, Berardi RR, DeSimone EM, eds. Handbook of nonprescription drugs 12th ed. 2000:183–184.
- Abramowicz M, Zuccotti G, Rizack MA, et al, editors. Phenylpropanolamine and other OTC alpha-adrenergic agonists. Med Lett Drugs Ther 2000; 42:113.

ADDRESS: Tracey L. Mersfelder, PharmD, 715 Xavier Hall, 220 Cherry Street SE, Grand Rapids, MI 49503.



IN THIS ISSUE PAGE 263